• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

    7/2/25 4:30:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XOMA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sitko Bradley

    (Last) (First) (Middle)
    C/O XOMA ROYALTY CORPORATION
    2200 POWELL STREET, SUITE 310

    (Street)
    EMERYVILLE CA 94608

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    XOMA Royalty Corp [ XOMA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Investment Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    06/30/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Depositary Shares - 8.375% Series B Cumulative Stock 06/30/2025 P 2,000 A $25.39(1) 7,045 D
    Common Stock 13,110(2) D
    8.625% Series A Cumulative Perpetual Preferred Stock 313 D
    Common Stock 829 I By 401(k) Plan
    Common Stock 1,500 I By spouse
    Common Stock 75 I By child
    Common Stock 75 I By child
    8.625% Series A Cumulative Perpetual Preferred Stock 82 I By spouse
    Depositary Shares - 8.375% Series B Cumulative Stock 2,000 I By spouse
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This transaction was executed in multiple trades at prices ranging from $25.39 to $25.40. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
    2. Includes 1,626 shares acquired under the ESPP Plan on May 31, 2025.
    Remarks:
    /s/ Thomas Burns, Attorney-in-Fact for Bradley Sitko 07/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $XOMA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $XOMA

    DatePrice TargetRatingAnalyst
    4/17/2025$35.00Buy
    The Benchmark Company
    4/29/2024$40.00Outperform
    Leerink Partners
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    9/7/2021$22.00Outperform → Neutral
    Wedbush
    9/7/2021$22.00Neutral → Underperform
    Wedbush
    6/29/2021$60.00Buy
    Aegis Capital
    More analyst ratings

    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

      EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

      6/27/25 7:30:00 AM ET
      $TSBX
      $XOMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • XOMA Royalty Declares Quarterly Preferred Stock Dividends

      EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.   Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.   The preferred dividends will be paid on or about July 15, 2025, t

      6/18/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

      EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million. "This transaction further builds the potential of XOMA Royalty's late-stage royalty portfolio by increasing our economics in a pr

      5/27/25 8:01:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      7/2/25 4:30:26 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/9/25 4:44:30 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/7/25 4:39:59 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

      The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

      4/17/25 8:34:06 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on XOMA with a new price target

      Leerink Partners initiated coverage of XOMA with a rating of Outperform and set a new price target of $40.00

      4/29/24 8:01:47 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on XOMA with a new price target

      HC Wainwright & Co. reiterated coverage of XOMA with a rating of Buy and set a new price target of $69.00 from $56.00 previously

      10/8/21 6:18:28 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      7/2/25 4:30:26 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kosacz Barbara was granted 5,971 shares (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      5/23/25 4:48:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wyszomierski Jack L was granted 5,971 shares, increasing direct ownership by 48% to 18,504 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      5/23/25 4:48:15 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Leadership Updates

    Live Leadership Updates

    See more
    • XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

      Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

      5/9/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

      EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.  Mr. Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023. "The rest of the Board and I have been impressed with Owen's leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator.  I am looking forward to working closely with Owen and the team to further accelerate the Company's growth and maximize value for all XOMA stockholders," stated

      1/8/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

      SC 13G/A - XOMA Corp (0000791908) (Subject)

      2/9/24 10:05:21 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by XOMA Corporation (Amendment)

      SC 13D/A - XOMA Corp (0000791908) (Subject)

      1/16/24 5:22:40 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

      SC 13G/A - XOMA Corp (0000791908) (Subject)

      2/9/23 12:46:50 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Financials

    Live finance-specific insights

    See more
    • Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

      EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

      6/27/25 7:30:00 AM ET
      $TSBX
      $XOMA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • XOMA Royalty Declares Quarterly Preferred Stock Dividends

      EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.   Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.   The preferred dividends will be paid on or about July 15, 2025, t

      6/18/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

      EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million. "This transaction further builds the potential of XOMA Royalty's late-stage royalty portfolio by increasing our economics in a pr

      5/27/25 8:01:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    SEC Filings

    See more
    • XOMA Royalty Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

      8-K - XOMA Royalty Corp (0000791908) (Filer)

      5/30/25 4:30:28 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by XOMA Royalty Corporation

      10-Q - XOMA Royalty Corp (0000791908) (Filer)

      5/13/25 7:45:36 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by XOMA Royalty Corporation

      8-K - XOMA Royalty Corp (0000791908) (Filer)

      5/13/25 7:45:25 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care